{
    "nct_id": "NCT03952078",
    "official_title": "A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma",
    "inclusion_criteria": "* Adult subjects age â‰¥18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically confirmed evidence of T-cell lymphoma\n* Measurable disease.\n* Adequate organ function.\n* At least 2 standard therapies for advanced or recurrent disease or had a disease for which there is no more than one established therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with systemic immunosuppressive medication.\n* History of allogeneic hematopoietic stem cell transplantation.\n* History of primary immunodeficiency, solid organ transplantation.\n* History of opportunistic infection within 180 days of starting study drug.\n* Females who are pregnant, lactating, or intend to become pregnant\n* History of invasive prior malignancy that required systemic therapy within last 3 years.\n* Concomitant use of strong inhibitors or inducers of CYP3A.",
    "miscellaneous_criteria": ""
}